What is Cloridrato de Propranolol Medquimica?
Cloridrato de Propranolol Medquimica is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure may reduce the risk of stroke and heart attacks.
Cloridrato de Propranolol Medquimica is also used to treat severe chest pain (angina), migraine headaches, or hypertrophic subaortic stenosis (thickened heart muscle).
Cloridrato de Propranolol Medquimica may also be used to treat irregular heartbeats, tremors, or pheochromocytoma (adrenal gland tumor). It may also be used to reduce the risk of death in patients who have heart attacks.
Cloridrato de Propranolol Medquimica oral solution is used to treat proliferating infantile hemangioma.
Cloridrato de Propranolol Medquimica is a beta-blocker. It works by affecting the response to nerve impulses in certain parts of the body, like the heart. As a result, the heart beats slower and decreases the blood pressure. When the blood pressure is lowered, the amount of blood and oxygen is increased to the heart.
Cloridrato de Propranolol Medquimica is available only with your doctor's prescription.
Cloridrato de Propranolol Medquimica indications
Hypertension
Cloridrato de Propranolol Medquimica is indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Cloridrato de Propranolol Medquimica is not indicated in the management of hypertensive emergencies.
Angina Pectoris Due to Coronary Atherosclerosis
Cloridrato de Propranolol Medquimica is indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris.
Atrial Fibrillation
Cloridrato de Propranolol Medquimica is indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response.
Myocardial Infarction
Cloridrato de Propranolol Medquimica is indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.
Migraine
Cloridrato de Propranolol Medquimica is indicated for the prophylaxis of common migraine headache. The efficacy of Cloridrato de Propranolol Medquimica in the treatment of a migraine attack that has started has not been established, and Cloridrato de Propranolol Medquimica is not indicated for such use.
Essential Tremor
Cloridrato de Propranolol Medquimica is indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Cloridrato de Propranolol Medquimica causes a reduction in the tremor amplitude, but not in the tremor frequency. Cloridrato de Propranolol Medquimica is not indicated for the treatment of tremor associated with Parkinsonism.
Hypertrophic Subaortic Stenosis
Cloridrato de Propranolol Medquimica improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.
Pheochromocytoma
Cloridrato de Propranolol Medquimica is indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors.
How should I use Cloridrato de Propranolol Medquimica?
Use Cloridrato de Propranolol Medquimica solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Cloridrato de Propranolol Medquimica solution comes with extra patient information sheets called a Medication Guide and Instructions for Use. Read them carefully. Read them again each time you get Cloridrato de Propranolol Medquimica solution refilled.
- Do NOT shake Cloridrato de Propranolol Medquimica solution before use.
- Use the syringe that comes with Cloridrato de Propranolol Medquimica solution to measure the dose. Ask the pharmacist for help if you are unsure of how to measure the dose.
- Give Cloridrato de Propranolol Medquimica solution right into your child's mouth. If needed, Cloridrato de Propranolol Medquimica solution may be mixed in a small amount of milk or fruit juice and given in a baby's bottle.
- Give Cloridrato de Propranolol Medquimica solution with or right after a feeding.
- Give doses of Cloridrato de Propranolol Medquimica solution at least 9 hours apart.
- The dose of Cloridrato de Propranolol Medquimica solution may need to be changed as your child's weight changes. Have your child's weight checked often. Talk with the doctor before changing your child's dose.
- Give Cloridrato de Propranolol Medquimica solution on a regular schedule to get the most benefit from it. Giving Cloridrato de Propranolol Medquimica solution at the same time each day will help you remember to give it.
- If your child spits up a dose or if you are not sure your child got all of the medicine, do not give another dose. Wait until the next scheduled dose.
- If you miss giving your child a dose of Cloridrato de Propranolol Medquimica solution, give it as soon as possible. If it is almost time for the next dose, skip giving the missed dose and go back to your child's regular dosing schedule. Do not give 2 doses at once.
Ask your health care provider any questions you may have about how to use Cloridrato de Propranolol Medquimica solution.
Uses of Cloridrato de Propranolol Medquimica in details
Use: Labeled Indications
Angina, chronic stable: To decrease angina frequency and increase exercise tolerance in patients with angina pectoris.
Cardiac arrhythmias: Control of supraventricular arrhythmias (eg, atrial fibrillation and flutter, atrioventricular nodal reentrant tachycardia) and ventricular tachycardias (eg, catecholamine-induced arrhythmias, digoxin toxicity).
Essential tremor: Management of familial or hereditary essential tremor.
Hypertension: Management of hypertension. Note: Beta-blockers are not recommended as first-line therapy (ACC/AHA [Whelton 2018]).
Migraine headache prophylaxis: Prophylaxis of common migraine headache.
Myocardial infarction, early treatment and secondary prevention: To reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable.
Obstructive hypertrophic cardiomyopathy: Symptomatic treatment of obstructive hypertrophic cardiomyopathy (formerly known as hypertrophic subaortic stenosis).
Pheochromocytoma: As an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors.
Proliferating infantile hemangioma (Cloridrato de Propranolol Medquimica): Treatment of proliferating infantile hemangioma requiring systemic therapy.
Off Label Uses
Akathisia, antipsychotic-induced
Data from a limited number of patients in 5 randomized, double-blind, controlled studies support the use of Cloridrato de Propranolol Medquimica in antipsychotic-induced akathisia.
Based on the American Association for the Study of Liver Diseases guidelines on the management of portal hypertensive bleeding in cirrhosis and the British Society of Gastroenterology guidelines on the management of variceal hemorrhage in cirrhotic patients, use of nonselective beta-blockers, such as Cloridrato de Propranolol Medquimica, is effective and recommended for primary and secondary prophylaxis of variceal hemorrhage.
Cloridrato de Propranolol Medquimica description
A widely used non-cardioselective beta-adrenergic antagonist. R,S-Cloridrato de Propranolol Medquimica Hydrochloride is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety.
Cloridrato de Propranolol Medquimica dosage
Cloridrato de Propranolol Medquimica Dosage
Generic name: Cloridrato de Propranolol Medquimica HYDROCHLORIDE 80mg
Dosage form: capsule, extended release
See also:
- Cloridrato de Propranolol Medquimica Tablets
- Cloridrato de Propranolol Medquimica capsule, extended release
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Cloridrato de Propranolol Medquimica should be administered once daily at bedtime and should be taken consistently either on an empty stomach or with food. Initiate dosing at 80 mg and titrate to 120 mg daily as needed for blood pressure control. Doses above 120 mg have no additional effects on blood pressure. The time needed for full antihypertensive response is variable, but is usually achieved within 2 to 3 weeks.
More about Cloridrato de Propranolol Medquimica (Cloridrato de Propranolol Medquimica)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 0 Reviews - Add your own review/rating
Consumer resources
- Cloridrato de Propranolol Medquimica
- Cloridrato de Propranolol Medquimica (Advanced Reading)
- Other brands: Cloridrato de Propranolol Medquimica, Cloridrato de Propranolol Medquimica, InnoPran XL, Cloridrato de Propranolol Medquimica
Professional resources
- Cloridrato de Propranolol Medquimica (FDA)
- Cloridrato de Propranolol Medquimica Hydrochloride (AHFS Monograph)
Related treatment guides
- Atrial Fibrillation
- Ventricular Tachycardia
Cloridrato de Propranolol Medquimica interactions
See also:
What other drugs will affect Cloridrato de Propranolol Medquimica?
Patients receiving catecholamine-depleting drugs such as reserpine should be closely observed if Beta-Cloridrato de Propranolol Medquimica HCl is administered. The added catecholamine-blocking action may produce an excessive reduction of resting sympathetic nervous activity, which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension.
Caution should be exercised when patients receiving a beta blocker are administered a calcium-channel blocking drug, especially intravenous verapamil, for both agents may depress myocardial contractility or atrioventricular conduction. On rare occasions, the concomitant intravenous use of a beta blocker and verapamil has resulted in serious adverse reactions, especially in patients with severe cardiomyopathy, congestive heart failure, or recent myocardial infarction.
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.
Hypotension and cardiac arrest have been reported with the concomitant use of Cloridrato de Propranolol Medquimica and haloperidol.
Aluminum hydroxide gel: Greatly reduces intestinal absorption of Cloridrato de Propranolol Medquimica.
Ethanol: Slows the rate of absorption of Cloridrato de Propranolol Medquimica.
Phenytoin, phenobarbitone: and rifampin accelerate Cloridrato de Propranolol Medquimica clearance.
Chlorpromazine: When used concomitantly with Cloridrato de Propranolol Medquimica, results in increased plasma levels of both drugs.
Antipyrine: and lidocaine have reduced clearance when used concomitantly with Cloridrato de Propranolol Medquimica.
Thyroxine: May result in a lower than expected T3 concentration when used concomitantly with Cloridrato de Propranolol Medquimica.
Cimetidine Decreases the hepatic metabolism of Cloridrato de Propranolol Medquimica, delaying elimination and incre:asing blood levels.
Theophylline: Clearance is reduced when used concomitantly with Cloridrato de Propranolol Medquimica.
Cloridrato de Propranolol Medquimica side effects
See also:
What are the possible side effects of Cloridrato de Propranolol Medquimica?
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
- Hypoglycemia and related events, like hypoglycemic seizure.
- Bronchospasm.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug may not reflect the rates observed in clinical practice.
Clinical Trials Experience with Cloridrato de Propranolol Medquimica in Infants with proliferating infantile hemangioma
In clinical trials for proliferating infantile hemangioma, the most frequently reported adverse reactions ( > 10%) in infants treated with Cloridrato de Propranolol Medquimica were sleep disorders, aggravated respiratory tract infections such as bronchitis and bronchiolitis associated with cough and fever, diarrhea, and vomiting. Adverse reactions led to treatment discontinuation in fewer than 2% of treated patients.
Overall, 479 patients in the pooled safety population were exposed to study drug in the clinical study program (456 in placebo-controlled trials). A total of 424 patients were treated with Cloridrato de Propranolol Medquimica at doses 1.2 mg/kg/day or 3.4 mg/kg/day for 3 or 6 months. Of these, 63% of patients were aged 91-150 days and 37% were aged 35-90 days at randomization.
The following table lists according to the dosage the most common adverse reactions (treatment-emergent adverse events with an incidence at least 3% greater on one of the two doses than on placebo).
Table 2: Treatment-emergent adverse events occurring at least 3% more often on Cloridrato de Propranolol Medquimica than on placebo.
| Reaction | Placebo N=236 | Cloridrato de Propranolol Medquimica 1.2 mg/kg/day N=200 | Cloridrato de Propranolol Medquimica 3.4 mg/kg/day N=224 |
| Sleep disorder | 5.90% | 17.50% | 16.10% |
| Bronchitis | 4.7 | 8 | 13.4 |
| Peripheral coldness | 0.4 | 8 | 6.7 |
| Agitation | 2.1 | 8.5 | 4.5 |
| Diarrhea | 1.3 | 4.5 | 6.3 |
| Somnolence | 0.4 | 5 | 0.9 |
| Nightmare | 1.7 | 2 | 6.3 |
| Irritability | 1.3 | 5.5 | 1.3 |
| Decreased appetite | 0.4 | 2.5 | 3.6 |
| Abdominal pain | 0.4 | 3.5 | 0.4 |
The following adverse events have been observed during clinical studies, with an incidence of less than 1%:
Cardiac disorders: Second degree atrioventricular heart block, in a patient with underlying conduction disorder, required definitive treatment discontinuation.
Skin and subcutaneous tissue disorders: Urticaria, alopecia
Investigations: Decreased blood glucose, decreased heart rate
Compassionate Use Program
More than 600 infants received Cloridrato de Propranolol Medquimica in a compassionate use program (CUP). Mean age at treatment initiation was 3.6 months. Mean dose of Cloridrato de Propranolol Medquimica was 2.2 mg/kg/day and mean treatment duration was 7.1 months.
The adverse reactions reported in the CUP were similar to the ADRs observed during clinical trials but some were more severe.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Cloridrato de Propranolol Medquimica. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
These adverse reactions are as follows:
Blood and lymphatic system disorders: Agranulocytosis
Psychiatric disorders: Hallucination
Skin and subcutaneous tissues disorders: Purpura
Cloridrato de Propranolol Medquimica contraindications
See also:
What is the most important information I should know about Cloridrato de Propranolol Medquimica?
You should not use this medication if you are allergic to Cloridrato de Propranolol Medquimica, if you have asthma, a slow heart rate, or a serious heart condition such as "sick sinus syndrome" or "AV block" (unless you have a pacemaker).
If you need surgery, tell the surgeon ahead of time that you are using Cloridrato de Propranolol Medquimica. You may need to stop using the medicine for a short time.
Do not skip doses or stop using Cloridrato de Propranolol Medquimica without first talking to your doctor. You may need to use less and less before you stop the medication completely.
Avoid drinking alcohol. It may increase your blood levels of Cloridrato de Propranolol Medquimica.
Cloridrato de Propranolol Medquimica is only part of a complete program of treatment for hypertension that may also include diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely if you are being treated for hypertension.
If you are being treated for high blood pressure, keep using this medication even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medication for the rest of your life.
Active ingredient matches for Cloridrato de Propranolol Medquimica:
Propranolol in Brazil.
List of Cloridrato de Propranolol Medquimica substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Cloridrato de Propranolol União Química (Brazil) | |
| Clotas Plus | |
| Clotas Plus 0.5+20 Tablet (Tas Med (I) Pvt. Ltd.) | $ 0.05 |
| CLOTAS PLUS 0.5 MG/20 MG TABLET 1 strip / 10 tablets each (Tas Med (I) Pvt. Ltd.) | $ 0.59 |
| Clotas Plus 0.5 mg/20 mg Tablet (Tas Med (I) Pvt. Ltd.) | $ 0.06 |
| Colliprol (Mexico) | |
| Corbeta (India) | |
| CORBETA Capsule/ Tablet / 40mg / 10 units (Nicholas Piramal India Ltd.) | $ 0.11 |
| Corbeta 10mg TAB / 10 (Nicholas Piramal India Ltd.) | $ 0.05 |
| Corbeta 40mg TAB / 10 (Nicholas Piramal India Ltd.) | $ 0.11 |
| 40 mg x 10's (Nicholas Piramal India Ltd.) | $ 0.11 |
| Corbeta 40 mg x 1's (Nicholas Piramal India Ltd.) | |
| Corbeta 80 mg x 1's (Nicholas Piramal India Ltd.) | |
| Tablets; Oral; Propranolol Hydrochloride 40 mg (Nicholas Piramal India Ltd.) | |
| Tablets; Oral; Propranolol Hydrochloride 80 mg (Nicholas Piramal India Ltd.) | |
| Corbeta 40 mg Tablet (Nicholas Piramal India Ltd.) | $ 0.01 |
| Corbeta 10 mg Tablet (Nicholas Piramal India Ltd.) | $ 0.00 |
| CORBETA tab 40 mg x 10's (Nicholas Piramal India Ltd.) | $ 0.11 |
| Corbeta 10mg Tablet (Nicholas Piramal India Ltd.) | $ 0.00 |
| Corbeta 40mg Tablet (Nicholas Piramal India Ltd.) | $ 0.01 |
| Coriodal (Chile) | |
| Tablet; Oral; Propranolol Hydrochloride 20 mg (Sanitas) | |
| Tablet; Oral; Propranolol Hydrochloride 40 mg (Sanitas) | |
| Tablets; Oral; Propranolol Hydrochloride 20 mg (Sanitas) | |
| Tablets; Oral; Propranolol Hydrochloride 40 mg (Sanitas) | |
| Corpendol (Portugal) | |
| Deminy | |
| Deminy 40 mg Tablet (Jpee Drugs) | $ 0.03 |
| Deralin (Australia, Israel) | |
| Tablet; Oral; Propranolol Hydrochloride 10 mg (Abic) | |
| Tablet; Oral; Propranolol Hydrochloride 160 mg (Abic) | |
| Tablet; Oral; Propranolol Hydrochloride 40 mg (Abic) | |
| Tablets; Oral; Propranolol Hydrochloride 10 mg (Abic) | |
| Tablets; Oral; Propranolol Hydrochloride 160 mg (Abic) | |
| Tablets; Oral; Propranolol Hydrochloride 40 mg (Abic) | |
| Deralin 10mg (Israel) | |
| Deralin 40mg (Israel) | |
| Detensol (Canada) | |
| Tablet; Oral; Propranolol Hydrochloride 10 mg (Desbergers) | |
| Tablet; Oral; Propranolol Hydrochloride 120 mg (Desbergers) | |
| Tablet; Oral; Propranolol Hydrochloride 40 mg (Desbergers) | |
| Tablet; Oral; Propranolol Hydrochloride 80 mg (Desbergers) | |
| Tablets; Oral; Propranolol Hydrochloride 10 mg (Desbergers) | |
| Tablets; Oral; Propranolol Hydrochloride 120 mg (Desbergers) | |
| Tablets; Oral; Propranolol Hydrochloride 40 mg (Desbergers) | |
| Tablets; Oral; Propranolol Hydrochloride 80 mg (Desbergers) | |
| Dideral (Turkey) | |
| Tablet; Oral; Propranolol Hydrochloride 40 mg (Sanofi synthelabo) | |
| Tablets; Oral; Propranolol Hydrochloride 40 mg (Sanofi synthelabo) | |
See 1267 substitutes for Cloridrato de Propranolol Medquimica | |
References
- PubChem. "propranolol". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "propranolol". http://www.drugbank.ca/drugs/DB00571 (accessed September 17, 2018).
- MeSH. "Vasodilator Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Cloridrato de Propranolol Medquimica are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Cloridrato de Propranolol Medquimica. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
